- Home
- IMXI vs PVLA Comparison
IMXI vs PVLA Comparison
Compare IMXI & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMXI
- PVLA
- Stock Information
- Founded
- IMXI 1994
- PVLA 2015
- Country
- IMXI United States
- PVLA United States
- Employees
- IMXI N/A
- PVLA N/A
- Industry
- IMXI Retail: Computer Software & Peripheral Equipment
- PVLA Biotechnology: Pharmaceutical Preparations
- Sector
- IMXI Technology
- PVLA Health Care
- Exchange
- IMXI Nasdaq
- PVLA Nasdaq
- Market Cap
- IMXI 278.2M
- PVLA 285.2M
- IPO Year
- IMXI N/A
- PVLA N/A
- Fundamental
- Price
- IMXI $14.50
- PVLA $54.15
- Analyst Decision
- IMXI Buy
- PVLA Strong Buy
- Analyst Count
- IMXI 6
- PVLA 11
- Target Price
- IMXI $19.60
- PVLA $56.64
- AVG Volume (30 Days)
- IMXI 1.3M
- PVLA 133.4K
- Earning Date
- IMXI 08-11-2025
- PVLA 08-14-2025
- Dividend Yield
- IMXI N/A
- PVLA N/A
- EPS Growth
- IMXI N/A
- PVLA N/A
- EPS
- IMXI 1.65
- PVLA N/A
- Revenue
- IMXI $642,149,000.00
- PVLA N/A
- Revenue This Year
- IMXI N/A
- PVLA N/A
- Revenue Next Year
- IMXI $1.87
- PVLA N/A
- P/E Ratio
- IMXI $8.80
- PVLA N/A
- Revenue Growth
- IMXI N/A
- PVLA N/A
- 52 Week Low
- IMXI $8.58
- PVLA $11.17
- 52 Week High
- IMXI $22.37
- PVLA $57.19
- Technical
- Relative Strength Index (RSI)
- IMXI 75.35
- PVLA 67.56
- Support Level
- IMXI $14.34
- PVLA $49.13
- Resistance Level
- IMXI $14.55
- PVLA $57.19
- Average True Range (ATR)
- IMXI 0.19
- PVLA 4.30
- MACD
- IMXI -0.01
- PVLA 0.15
- Stochastic Oscillator
- IMXI 19.05
- PVLA 81.32
About IMXI International Money Express Inc.
International Money Express Inc is a processor of money transfer services in the USA to the Latin America and the Caribbean (LAC) corridor. The company offers wire transfer, money order, Foreign exchange, and cash checking services, while the majority of the revenue is derived from wire transfer and money order fees. The firm's business is organized around one reportable segment that provides money remittance services between the U.S. and Canada to Mexico, Guatemala, and other countries in Latin America, Africa, and Asia.
About PVLA Palvella Therapeutics Inc. Common Stock
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.